News from bionomics limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 24, 2018, 09:00 ET Commencement of BNC210 Phase 2 Clinical Trial for the Treatment of Agitation

Bionomics Limited (ASX:BNO) (OTCQX:BNOEF), a global, clinical stage biopharmaceutical company, today announces that a Phase 2 clinical trial of its...


Feb 03, 2017, 05:00 ET Bionomics to Receive Milestone Payment from MSD for Initiation of Phase 1 Clinical Study of Candidate Alzheimer's Treatment

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the...


Dec 08, 2015, 06:00 ET Post Traumatic Stress Disorder Identified as Major New Market Opportunity for BNC210

A substantial additional market opportunity for BNC210 has been identified and will be developed via a Phase 2 trial funded by a US$12m placement...


Nov 13, 2015, 06:00 ET Bionomics and MSD Hosting Cognition and Alzheimer's Symposium Featuring Australian and US Speakers

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the...


Oct 08, 2015, 06:00 ET Bionomics Announces Extension of Strategic Collaboration with Merck & Co., Inc. for the Discovery and Development of Novel Pain Medications

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the...


Sep 16, 2015, 06:00 ET Bionomics Reports Positive Data from Phase 1 Multiple Ascending Dose Trial of BNC210 for Anxiety and Depression

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the...


Aug 31, 2015, 06:00 ET Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate

Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the...


Jun 15, 2015, 06:00 ET Bionomics Files Patent For Use Of BNC105 In Combination With PD-1 And CTLA-4 Immuno-Oncology Antibodies

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the...


Apr 20, 2015, 06:00 ET Bionomics Initiates Phase II Clinical Trial of BNC210 for Treatment of Anxiety

Bionomics Limited (ASX: BNO, OTCQX: BNOEF) , a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the...


Apr 17, 2015, 06:00 ET Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting

Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the...


Apr 10, 2015, 06:00 ET BNC105 Biomarker Data to Be Presented at Asian Oncology Conference

Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced that it will present a poster with new data on the DisrupTOR-1 trial of BNC105 in patients ...


Mar 02, 2015, 08:00 ET Bionomics Begins Trading on OTCQX Marketplace

Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced its ordinary shares commenced trading on the OTCQX marketplace in the U.S., effective...


Feb 27, 2015, 08:00 ET New BNC105 Biomarker Data to be Presented at US Cancer Conference

Bionomics Limited (ASX:BNO, ADR:BMICY) is to present important additional data from the DisrupTOR-1 trial of BNC105 in patients with metastatic renal ...


Feb 02, 2015, 06:00 ET Bionomics Begins Phase 1b Study With Anxiety Drug Bnc210

Bionomics Limited (ASX:BNO) has initiated a Phase 1b clinical trial in healthy volunteers of BNC210, the Company's drug candidate in development for...


Jun 23, 2014, 07:17 ET Bionomics and Merck Enter New Research Collaboration

Bionomics Limited (ASX:BNO, ADR:BMICY) announces that it has entered into an exclusive Research Collaboration and License Agreement with Merck, known ...